| Document |
Document Title |
|
WO/2018/188795A1 |
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.
|
|
WO/2018/186040A1 |
Provided is an ionic liquid, characterized in containing a cationic component and an anionic component, and in that the cationic component comprises a group having a perfluoropolyether chain and a group having a hydroxyl group.
|
|
WO/2018/181986A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/181884A1 |
The objective of the present invention is to provide a novel compound inhibiting the entry of a filovirus into a cell, a medical composition, an anti-filovirus agent, or a filovirus entry inhibitor containing the compound, as well as a m...
|
|
WO/2018/179343A1 |
The present invention provides a pharmaceutical composition for treating or preventing cognitive function disease or disorder, the composition comprising a compound represented by formula (I), an enantiomer thereof, a diastereomer thereo...
|
|
WO/2018/176134A1 |
The present disclosure relates to compounds for use as electrode additives or as salts in electrolyte compositions, and their methods of preparation. The majority of compounds are anions of imidazoles bearing a sulphonyl or a carbonyl gr...
|
|
WO/2018/175682A1 |
The disclosure provides methods and compositions therefor for treating a surface wherein a surface treatment layer is formed on the surface, thereby minimizing or preventing pattern collapse as the surface is subjected to typical cleanin...
|
|
WO/2018/169252A1 |
The present invention relates to an N-benzyl-N-phenoxyl carbonyl-phenyl sulfonamide derivative, which inhibits PGE2 generation by means of inhibiting microsomal prostaglandin E2 synthase-1 (mPGES-1) and has enhanced activity, a method fo...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/161892A1 |
A benzene sulfonamide compound having structural features of formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Experimental res...
|
|
WO/2018/159640A1 |
Provided are: a curable composition including a salt compound provided with a) an organic anion of which the values of the Hansen solubility parameters δd, δp, and δH are respectively 16 or higher, in the range of 16-32 inclusive, and...
|
|
WO/2018/157240A1 |
The disclosure relates to a compound of formula: (I) Several different uses of this compound are described for preparing different compounds. For example, this compound makes it possible to graft a fluorosulfonyl group on a molecule. A m...
|
|
WO/2018/159650A1 |
The purpose of the present invention is to provide a compound which has a guanidine skeleton and inhibits the protease activity of MALT1 to exhibit a therapeutic effect or prophylactic effect on autoimmune diseases such as psoriasis. The...
|
|
WO/2018/156297A1 |
The present invention related to novel sulfonamides or amides as TLR-4 antagonists, and pharmaceutical formulations containing the same and the methods of use thereof. Uses of the present novel sulfonamides or amides include, but are not...
|
|
WO/2018/154519A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/145620A1 |
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to pro...
|
|
WO/2018/145874A1 |
The invention relates to a compound of the formula (I) Ar(NHSO2Ar1)l(SO2NHAr1)m(NHC(O)NHAr2)n (I), wherein l and m independently of one another are 0, 1, 2, 3, and/or 4 and the sum of l+m is equal to or more than 1, n is 2, 3, 4, or 5, A...
|
|
WO/2018/130625A1 |
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...
|
|
WO/2018/129556A1 |
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...
|
|
WO/2018/128720A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2018/117467A1 |
Disclosed in the specification is a method which selectively separates an R type enantiomer contained in a racemate (R/S=1/1) of N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide
, and then can convert the same back into the r...
|
|
WO/2018/118827A1 |
The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the tr...
|
|
WO/2018/107289A1 |
Compounds described herein are inhibitors of retinoic acid inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids. Certain compounds have retinoid activity, are resistant to CYP26-mediated c...
|
|
WO/2018/104307A1 |
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...
|
|
WO/2018/104305A1 |
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...
|
|
WO/2018/103583A1 |
Inhibitors with anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis and autoinflammatory...
|
|
WO/2018/102419A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
|
WO/2018/095488A1 |
The invention relates to sulfobetaine compounds, a process for synthesizing same, and the uses of sulfobetaine compounds for synthesizing antimicrobial materials, antistatic materials, antifouling materials, printing inks, surface-active...
|
|
WO/2018/098209A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2018/093694A1 |
Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also ...
|
|
WO/2018/086531A1 |
Disclosed are a series of sulfonamides compounds, represented by general formulas (I) and (II), serving as cccDNA inhibitors, and tautomers or pharmacologically acceptable salts thereof.
|
|
WO/2018/086507A1 |
The invention discloses a naphthalene sulfonamide type compound, a preparation method thereof and an application thereof for regulating plant growth activity. A general formula of a structure of the naphthalene sulfonamide type compound ...
|
|
WO/2018/085171A1 |
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...
|
|
WO/2018/085170A1 |
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...
|
|
WO/2018/078657A1 |
The present invention discloses a simple, economic, consistent, commercially viable and industrially applicable process for preparation of Glipizide in high yield and highly pure Glipizide having purity more than 95%, preferably more tha...
|
|
WO/2018/072024A1 |
The invention relates to methods for the production of sulphamic acid derivatives, for example, halogenated derivatives and the salts thereof, metallic or organic, are described. The present application also relates to the resulting sulp...
|
|
WO/2018/068295A1 |
Substituted aryl and heteroaryl ether compounds of the Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R 1, R 2, R 3, L, R 4, L 1, Q, and R 5 are as defined herein. These compounds and pharmaceutically acceptable co...
|
|
WO/2018/071327A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2018/059491A1 |
Disclosed are an ionic liquid compound, an ionic liquid polymer prepared from the ionic liquid compound, a solid state electrolyte containing the polymer, an electrode binder for a battery, and a battery. Specifically, provided are an io...
|
|
WO/2018/062799A1 |
Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-
2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ell...
|
|
WO/2018/053080A1 |
Acute kidney injury (AKI) is often associated with damage to remote organs, such as lungs or heart. AKI induces kidney tubular necrosis as well as NETosis, programmed neutrophil death leading to neutrophil extracellular traps (NETs). His...
|
|
WO/2018/050631A1 |
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...
|
|
WO/2018/048675A1 |
Described are compounds of the formula: wherein RAryl is an aryl group; R1 is a linear or branched C2-C40 hydrocarbyl group; R2 is a C1-C4 alkyl; Rfis a perfluorinated group of having an average of 3 to 5 carbon atoms; and subscript x is...
|
|
WO/2018/044663A1 |
Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated dis...
|
|
WO/2018/043400A1 |
A compound represented by formula (I) or a salt thereof. In formula (I), each of R1 and R4 independently represents a hydrogen atom, an unsubstituted or substituted C1-6 alkyl group or the like; R2 represents a hydrogen atom, an unsubsti...
|
|
WO/2018/042894A1 |
Provided is a novel m-phenylenediamine compound which is useful as a starting material for the synthesis of a functional polymer compound, or the like. Also provided is a method for producing a polymer compound, which uses this novel m-p...
|
|
WO/2018/029150A1 |
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...
|
|
WO/2018/029699A1 |
The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.
|
|
WO/2018/018863A1 |
Disclosed are a mild and efficient preparation method for an α-acyloxy alkenyl amide compound and a use thereof in the synthesis of an amide and a polypeptide. The α-acyloxy alkenyl amide compound is obtained by an addition reaction of...
|
|
WO/2018/018091A1 |
The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.
|
